Insmed, Inc. (NASDAQ:INSM) Stock Holdings Raised by Duquesne Family Office LLC

Duquesne Family Office LLC lifted its holdings in Insmed, Inc. (NASDAQ:INSM - Free Report) by 130.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,369,050 shares of the biopharmaceutical company's stock after buying an additional 775,580 shares during the quarter. Insmed makes up about 3.4% of Duquesne Family Office LLC's holdings, making the stock its 8th biggest holding. Duquesne Family Office LLC owned 0.75% of Insmed worth $104,445,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. National Bank of Canada FI grew its holdings in Insmed by 9.7% during the 4th quarter. National Bank of Canada FI now owns 1,668 shares of the biopharmaceutical company's stock valued at $115,000 after buying an additional 147 shares in the last quarter. M&T Bank Corp lifted its position in shares of Insmed by 4.7% during the first quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company's stock worth $252,000 after purchasing an additional 147 shares during the last quarter. Snowden Capital Advisors LLC lifted its position in shares of Insmed by 2.5% during the fourth quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company's stock worth $456,000 after purchasing an additional 158 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its position in shares of Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 163 shares during the last quarter. Finally, Cullen Frost Bankers Inc. lifted its position in shares of Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 221 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages have commented on INSM. Leerink Partners boosted their target price on shares of Insmed from $100.00 to $115.00 and gave the stock an "outperform" rating in a report on Tuesday, June 10th. UBS Group reduced their target price on shares of Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a report on Friday, May 9th. HC Wainwright boosted their target price on shares of Insmed from $90.00 to $120.00 and gave the stock a "buy" rating in a report on Wednesday, June 11th. Wells Fargo & Company boosted their target price on shares of Insmed from $107.00 to $119.00 and gave the stock an "overweight" rating in a report on Wednesday, June 11th. Finally, The Goldman Sachs Group boosted their target price on shares of Insmed from $100.00 to $112.00 and gave the stock a "buy" rating in a report on Wednesday, June 11th. One research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, Insmed currently has a consensus rating of "Moderate Buy" and an average price target of $108.07.

Insmed Stock Up 1.7%

Shares of NASDAQ INSM traded up $1.72 during midday trading on Wednesday, hitting $104.59. 3,691,327 shares of the company's stock were exchanged, compared to its average volume of 2,301,643. The company has a debt-to-equity ratio of 11.38, a current ratio of 5.86 and a quick ratio of 5.44. Insmed, Inc. has a twelve month low of $60.40 and a twelve month high of $106.83. The company has a market cap of $19.84 billion, a PE ratio of -17.58 and a beta of 0.90. The firm's fifty day simple moving average is $85.41 and its 200-day simple moving average is $78.02.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). Insmed had a negative net margin of 265.93% and a negative return on equity of 446.98%. The firm had revenue of $92.82 million during the quarter, compared to analysts' expectations of $91.63 million. During the same quarter in the prior year, the firm posted ($1.06) EPS. Insmed's quarterly revenue was up 22.9% compared to the same quarter last year. Research analysts predict that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insider Buying and Selling at Insmed

In related news, Director David W. J. Mcgirr sold 3,000 shares of the stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $73.27, for a total transaction of $219,810.00. Following the transaction, the director directly owned 97,723 shares in the company, valued at approximately $7,160,164.21. This represents a 2.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO William Lewis sold 6,830 shares of the stock in a transaction dated Tuesday, July 15th. The stock was sold at an average price of $102.37, for a total value of $699,187.10. Following the transaction, the chief executive officer owned 233,924 shares in the company, valued at $23,946,799.88. This trade represents a 2.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 548,197 shares of company stock valued at $49,124,834. Corporate insiders own 3.00% of the company's stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.